Finding bioactive short peptides derived from proteins is a critical step to the advancement of tissue engineering and regenerative medicine, because the former maintains the functions of the latter without immunogenicity in biological systems. Here, we discovered a bioactive core nonapeptide sequence, PPFEGCIWN (residues 2678-2686; Ln2-LG3-P2-DN3), from the human laminin α2 chain, and investigated the role of this peptide in binding to transmembrane proteins to promote intracellular events leading to cell functions. This minimum bioactive sequence had neither secondary nor tertiary structures in a computational structure prediction. Nonetheless, Ln2-LG3-P2-DN3 bound to various cell types as actively as laminin in cell adhesion assays. The in vivo healing tests using rats revealed that Ln2-LG3-P2-DN3 promoted bone formation without any recognizable antigenic activity. Ln2-
Introduction
Complications, including graft rejection, donor site morbidity, and inadequate tissue formation, depending on the health status of each patient, limit current grafting methods to repair damaged tissues [1, 2] . Tissue engineering is an exciting new approach that can overcome the limitations of tissue transplantation, providing man-made tissues to patients in need [3, 4] . Several challenges have to be solved for a tissue-engineered material to be clinically applied; achieving appropriate functional activity without triggering an immune reaction is one of the most important goals. An example of an undesirable immune reaction is the recombinant human bone morphogenetic protein (rhBMP)-2, which is associated with early osteolysis, a kind of immunologic reaction, despite its enhanced bone formation effect [5, 6] . The result is the sinking of an adjacent implanted material into the marrow [6] .
was quantified by counting the number of cells that had migrated through the filter. Human placental laminin, rLG3, and Ln2-LG3-P2 were used as the positive controls and scrambled peptide (SP) was used as the negative control.
Quantitative real-time polymerase chain reaction
The mRNA levels of specific marker genes were determined by reverse transcription polymerase chain reaction (RT-PCR). Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. The RNA was denatured by incubation at 70 ˚C for 10 min and was kept on ice for 5 min. The cDNA was then prepared using SuperScript™ III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) and a random hexamer (Fermentas, Hanover, MD, USA) and was then subjected to real-time PCR amplification using SYBR ® Premix Ex Taq™ (Takara, Shiga, Japan) that contained a final concentration of 300 nM for each primer and a quantity of cDNA corresponding to 133 ng of total RNA. Quantitative real-time PCR (qRT-PCR) was performed using the 7300 Real-Time PCR System (Applied Biosystems). Primer sequences were designed using the Primer Express ® Software version 3.0 (Applied Biosystems). The PCR primers used were as follows: alkaline phosphatase (ALP), 5'-CCCACGTCGATTGCATCTCT-3' (sense) and analysis. The relative expressions of each target mRNA were calculated using the comparative cycle threshold method according to the manufacturer's instructions (Applied Biosystems).
Histological examination of inflammatory response in peptide-treated rats
All murine experiments and procedures were performed according to protocols approved by the Animal Care Committee of the Institute of Laboratory Animal Resources of Seoul National University (approval number: SNU-130204-1). To determine the inflammatory response of the peptides, we used eight-week-old male Sprague-Dawley rats (n = 3 rats per group). All peptides (Ln2-LG3-P2-DN3 and Ln2-LG3-P2) were dissolved in dimethyl sulfoxide (DMSO) and then diluted with DDW. Absorbable collagen sponges (BiolandKorea, Cheonan, Korea) were cut out with a punch (8 mm in diameter), treated with peptides (1.0 mg/cm 2 , 15 μl volume) or the vehicle alone (15 μl of DMSO), and dried for 24 h at room temperature. After each rat was anesthetized with an intraperitoneal injection of a Zoletil 50 (31.3 mg/kg) and Rompun (9.9 mg/kg) mixture, two full-thickness skin wounds were made on its back. Absorbable collagen sponges treated with the vehicle or peptides were applied to each wound and fixed with sutures. On the third day post-operation, the wounds were removed after euthanizing the rats. The harvested tissue was fixed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E). To ensure a representative sample, each wound sample was divided into quarters, and one field per quarter was sectioned and stained with H&E.
Animal experiments to evaluate new bone formation
For critical-size calvarial defects, eight-week-old male Sprague-Dawley rats (n = 4 rats per group) were used. Ln2-LG3-P2-DN3 and SP were dissolved in DMSO and then diluted with DDW.
Absorbable collagen sponges (BiolandKorea) were treated with recombinant human BMP-2 (4 μg/cm 2 , 15 μl volume; Pepro-Tech) or peptides (0.5 and 1.0 mg/cm 2 , 15 μl volume). The surgical procedures for the creation of an 8-mm circular defect in the central parietal bone and implantation of the collagen sponge were carried out as described previously [28] . The rats were euthanized at three weeks after surgery, and whole calvaria were fixed in 4% paraformaldehyde for 24 h at 4 °C and then analyzed by micro-computed tomographic (μCT) scanning. Details of the μCT scans are illustrated as described elsewhere. The specimens were then decalcified with 12% EDTA for two weeks and embedded in paraffin. The paraffin-embedded samples were sectioned at a thickness of 6 μm and stained with Masson's trichrome.
Histomorphometric and μCT analyses
The μCT was performed with an SMX-90CT system (90 kVp, 109 mA, and 180-ms integration time; Shimadzu, Kyoto, Japan). Scans were integrated into three-dimensional voxel images (1024 × 1024 pixel matrices). All bone images were reconstructed by the VG Studio MAX 1.2.1 program (Volume Graphics, Heidelberg, Germany) using standard procedures. The regenerated bone volume/tissue volume (%) was calculated and expressed with TRI/3D-VIE (RATOC System Engineering, Kyoto, Japan) according to standard formulas and nomenclature. The bone recovery rate (%) and calvarial thickness (mm) were calculated with OsteoMeasure XP Version 1.01 (OsteoMetrics, Decatur, GA, USA) according to standardized protocols.
Scanning electron microscopy
Pure Ti surfaces, without any modifications, were used in all experiments. Ti discs (20 mm in diameter, 0.5 mm thick) were placed in 12-well plates (Nunc), with one disc per well. The culture plates containing the Ti discs were coated with BSA (1%), human placental laminin (1.4 μg/cm 2 ), or synthetic peptides (14.3 μg/cm 2 ) by drying for 24 h at room temperature, then blocked with 1% heatinactivated BSA in PBS for 1 h at 37 °C, and finally washed with PBS. Cells (2 × 10 5 cells/ml) were added to the Ti discs coated with peptides and incubated for 1 h at 37 ºC in a 5% CO2 atmosphere.
After incubation, unattached cells were removed by rinsing the plates once with PBS. Attached cells were fixed with 10% formalin in PBS for 15 min and then stained with 0.5% crystal violet for 1 h.
The Ti discs were transferred to new 12-well plates and gently rinsed three times with DDW, after which the contents of each plate were solubilized in 2% SDS for 5 min. Absorbance was measured at 570 nm with a microplate reader (Bio-Rad).
Scanning electron microscopy (SEM) was used to examine the spreading of human osteogenic cells cultured onto the Ti surfaces. Cells (1 × 10 5 cells/1 ml) were added to each substrate-coated Ti disc and incubated for 3 h at 37 ºC. After incubation, unattached cells were removed by rinsing the plates once with PBS. Attached cells were fixed with 4% paraformaldehyde in PBS for 15 min, and the fixative was then aspirated. After a buffer wash, the Ti discs were dehydrated in a graded series of ethanol solutions. After critical point drying (HCP-2, Hitachi, Tokyo, Japan), the samples were sputtered with Au/Pd using an SEM coating system (Quorum Q150T-S, Quorum Technologies, West Sussex, UK), and the probes were examined by field emission-SEM (FE-SEM; Hitachi S-4700, Hitachi) at 15 kV. To ensure a representative count, each Ti disc was divided into quarters and one field per quarter was photographed using FE-SEM and counted.
ALP assay
The 60-mm culture dishes containing the Ti discs (50 mm in diameter, 0. that were prepared from commercially pure grade 4 Ti (Warrantec) were used without further surface modifications for the animal experiment. We used twelve male New Zealand white rabbits that ranged in age from one to two years old (2.5-3.5 kg). The rabbits showed no signs of disease. The anesthetic procedures, preparation of the surgical sites, and drilling for implant insertion were performed as described previously [29] . Drilling was done at the upper cortex only. The diameter of the holes drilled for implant insertion was 3.2 mm. Forty-eight pure, screw-shaped Ti implants were used. Of the 48 implants, 12 were treated with SP, 12 were treated with Ln2-LG3-P2, and 12 were treated with Ln2-LG3-P2-DN3. The Ti implants were placed on 0.2-ml PCR tubes and coated with the peptides (1 mg/cm 2 ) by drying for 10 d in a vacuum at room temperature. To determine the coating efficiency of the peptides (Ln2-LG3-P2 and Ln2-LG3-P2-DN3) onto the Ti implant, peptide-coated Ti implants were transferred to new PCR tubes and washed twice for 15 min in DDW at room temperature. The amount of remaining peptide was determined using a BCA TM protein assay kit (Thermo Scientific, Rockford, IL, USA). The remaining 12 implants, which had pure Ti surfaces without further surface modifications, served as negative controls. Each rabbit received four implants, which included one from each of the four groups. Two implants were inserted in the right tibia and two implants were inserted in the left tibia. The implants were assigned according to a 4 x 4 Latin square (Suppl. Fig. 1 ).
The implants penetrated the first cortical layer only. The periosteum and fascia were sutured with 4-0 chromic gut, and the skin was sutured with 4-0 silk (Ethicon, Somerville, NJ, USA).
Histological assessment
The animals were anesthetized and sacrificed by intravenous administration of potassium chloride for histomorphometry. Four rabbits were sacrificed at each of three time periods: one, two, and four weeks after implant insertion. The implants were surgically removed en bloc with an adjacent bone collar and immediately fixed in 4% neutral formaldehyde. The histomorphometric specimens were prepared as described previously [29] . The bone-to-implant contact (BIC) ratio was measured in the best three consecutive threads using a light microscope (Olympus BX microscope, Olympus, Tokyo, Japan) and image analysis software (Kappa Imagebase, Kappa Opto-electronics GmbH, Gleichen, Germany). The measurements were performed at 100 magnification.
In addition, the sections were stained using a modified Goldner's Masson trichrome staining technique and ALP histochemistry. We assayed collagen deposition using this technique, because it can detect collagen deposition on the undecalcified bone specimens [30] . Briefly, the sections were
Results

Identification of the bioactive core binding sequence in RNIPPFEGCIWN (Ln2-LG3-P2)
To determine the minimum bioactive sequence, synthetic peptides were prepared from Ln2-LG3-P2 ( LG3-P2-DN3 ( Fig. 1B-D) .
Because Ln2-LG3-P2-DN3 displayed cell adhesion activity in PC-12 cells, we further investigated whether Ln2-LG3-P2-DN3 would mediate the adhesion of other types of cells. Ln2-LG3-P2-DN3 at 11.4 μg/cm 2 displayed strong cell adhesion activity to NHEKs, NHOKs, NHDFs, NHOFs, human Schwann cells, MC3T3-E1, NIH/3T3, and CV-1 cells (Fig. 1E) , demonstrating a broad cell-type specificity of adhesion. Computations for the peptide structures predicted no specific secondary or tertiary structure for either Ln2-LG3-P2-DN3 or Ln2-LG3-P2 (data not shown). Taken together, these results indicate that the Ln2-LG3-P2-DN3 motif within the human laminin α2 LG3 domain is the bioactive core binding sequence without a specific conformational structure, which is important for the cellular responses of various cell types.
Effects of Ln2-LG3-P2-DN3 motif on osteogenic cellular responses
To confirm that Ln2-LG3-P2-DN3 promoted cellular responses in PC-12 cells, this study used SKPs obtained from human foreskin and verified their differentiation to mesenchymal cells and then to osteogenic cells. The differentiated osteogenic cells formed aggregates or nodules, and calcium accumulation was evident after two weeks. Alizarin red S staining demonstrated that mineral deposits were associated with some of these nodules. These mineral deposits were abundant at two weeks and were localized both to cells in the nodules and to some cells that grew in monolayers ( Fig. 2A) . In addition, qRT-PCR analysis revealed a ~74-fold increase in ALP expression in the differentiated osteogenic cells compared to the SKP-derived mesenchymal cells (Fig. 2B) . Next, we assessed the expression of osteogenic markers [22] , including osteonectin, type I collagen, BSP, RUNX2, and osteocalcin. The expression levels of the osteogenic markers tested were significantly upregulated in the differentiated cells (Fig. 2B) . These results clearly indicate that the SKP-derived cells differentiated into an osteogenic lineage. In the following experiments, these differentiated osteogenic cells were used as human osteogenic cells.
The adhesion of human osteogenic cells and osteoblast-like cells was evaluated using a cell adhesion assay in serum-free medium. Ln2-LG3-P2-DN3 and one of its mother molecules, Ln2-LG3-P2, significantly promoted the cell adhesion of osteogenic cells and osteoblast-like HOS and MG63 cells as compared with the SP-treated controls ( Fig. 2C and D ; Suppl. Fig. 2A and B) . Culture plates coated with Ln2-LG3-P2-DN3 and Ln2-LG3-P2 showed significantly higher cell spreading of osteogenic cells and osteoblast-like cells than did those treated with SP ( Fig. 2E ; Suppl. Fig. 2C ).
Ln2-LG3-P2-DN3 significantly induced ALP activity compared with the vehicle control, although ALP activity in Ln2-LG3-P2-DN3 was lower than that was observed in rhBMP2 (Fig. 2F) . These results support the hypothesis that Ln2-LG3-P2-DN3 is functionally active in promoting osteoblastic responses, which are important for bone formation and healing.
Effects of the Ln2-LG3-P2-DN3 motif on antigenicity
Because the inflammatory response is one of the most important factors for early-stage wound healing using tissue-engineering approaches [32] , the inflammatory responses during early-stage wound healing were compared in rats transplanted with absorbable collagen sponges treated with vehicle or peptides. In the vehicle-treated rats, inflammatory cells consistently infiltrated into the tissues adjacent to the inner surfaces of the absorbable collagen sponges (Fig. 3A and B) . The number of infiltrating inflammatory cells in both Ln2-LG3-P2-DN3-and Ln2-LG3-P2-treated rats was similar to that in the vehicle-treated rats ( Fig. 3A and B ). There were no multinucleated foreign body giant cells in either the vehicle-or peptide-treated rats. These findings confirm that Ln2-LG3-P2-DN3 has low or no antigenicity.
Effects of Ln2-LG3-P2-DN3 motif on healing of bone defects
To investigate whether Ln2-LG3-P2-DN3 promotes the osteogenic capacity to repair bone defects in vivo, the critical-size calvarial defect model in rats was used. The μCT images of the calvarial defects demonstrated that the SP-treated rats showed limited new bone formation at the defect sites three weeks after surgery, whereas the Ln2-LG3-P2-DN3-treated rats showed significant bone healing.
The amounts of newly generated bone in the rats treated with 0.5 and 1.0 mg/cm 2 of Ln2-LG3-P2-DN3 were significantly increased compared with the SP-treated controls (Fig. 4A) . Quantitative bone morphometric analyses revealed that Ln2-LG3-P2-DN3 increased both bone area (Fig. 4B ) and volume (Fig. 4C ). Masson's trichrome-stained histologic sections and quantitative histomorphometry for calvarial thickness confirmed greater amounts of bone regeneration in the Ln2-LG3-P2-DN3-treated rats than in the SP-treated controls ( Fig. 4D and E ). These results demonstrate that Ln2-LG3-
P2-DN3 promotes new bone formation in vivo.
The osteogenic potential of Ln2-LG3-P2-DN3 was further assessed in vivo using the rabbit tibia model and the Ln2-LG3-P2-DN3-treated Ti implants, which had the clinically applicable shape and dimensions. Because synthetic peptides that mimic extracellular matrix proteins function via signal transduction through cell membrane receptors [16, 26] , the amount of peptides applied onto scaffolds is important for their biological function. Therefore, the coating efficiency of the peptides onto the Ti implants was determined; approximately 85.9% of the peptides were coated onto the Ti implants after dry coating (data not shown). There was no inflammation of the bone near the inserted implants at the time of sacrifice in the experimental animals. In light microscopy, no inflammatory cells or multinucleated foreign body giant cells were found around the implants (Fig. 6A ).
Newly formed cancellous bone was found between the threads of the Ln2-LG3-P2-DN3-and Ln2-
LG3-P2-treated implants at one week after implant insertion, while little new bone was found in the pure Ti and SP-treated implants (Fig. 6A, upper) . More cancellous bone had formed after two weeks of healing, with new bone tissue slowly forming in the pure Ti and SP-treated implants (Fig. 6A, middle). New cortical bone was formed in all groups at four weeks after implant placement, and the mature bone was anchored to the implant surface (Fig. 6A, lower) . Fig. 6B shows the BIC ratio in each group. Whether the implant was installed on the right or left side did not affect the results (data not shown). As expected, the healing period affected the BIC ratio, with longer healing times corresponding to higher BIC ratios (Fig. 6B) . The pure Ti and SP-treated implants had the lowest BIC ratios throughout the experimental period after implant insertion; the Ln2-LG3-P2-DN3-treated implant showed significantly higher BIC ratio than the pure Ti and SP-treated implants did after both one and four weeks of healing (Fig. 6B) . Similarly, the Ln2-LG3-P2-DN3-treated implant had a tendency toward more favorable bone response after two weeks of healing than the pure Ti and SPtreated implants despite of no statistically significant differences in BIC (Fig. 6B ).
To confirm new bone formation around the implants, collagen deposition was determined in the threads of the implant using modified Goldner's Masson trichrome staining, which is an appropriate
Discussion
This study identified the minimum bioactive sequence, the PPFEGCIWN motif, for cell adhesion from the active sites of the laminin α2 chain. It also demonstrated the biological activities and effects of Ln2-LG3-P2-DN3 on tissue regeneration, especially bone regeneration, which had not been previously studied. Furthermore, this study showed that this minimum bioactive sequence with nine amino acids was significantly higher in ALP activity than Ln2-LG3-P2, the original sequence with 12 amino acids, was. These findings are highly meaningful because initial cell adhesion and spreading play an important role in early-stage wound healing, and because bioactive peptides are recognized as valuable scientific tools in the field of tissue engineering due to their ability to improve the functional activity of the scaffold and to bypass or minimize immune rejection [23, 30, 33] . The comparison with the vehicle control and rhBMP-2 clearly indicated the bone forming capability of this peptide.
rhBMP-2 is considered to be stronger in bone formation because it is a cytokine directly switching on the bone forming mechanism. However, rhBMP-2 is inapplicable on the implant surface due to uncoatability on the Ti surface, and no contribution to the cell adhesion. The Ln2-LG3-P2-DN3 motif acted as an effective bioactive peptide for bone formation and osseointegration, especially by stimulating osteoblast differentiation through increased ALP activity or expression.
To date, Ln2-LG3-P2-DN3 is the only active site that displays biological functions within the human laminin α2 LG3 domain. The Ln2-LG3-P2-DN3 sequence within the LG3 domain was located in the connecting loop of the K and L strands of the human laminin α2 chain [17] . This is partially consistent with a previous report [31] showing that alignment of LG sequences was localized to the GD-6 peptide (KQNCLSSRASFRGCVRNLRLSR, residues 3011-3032) from the C-terminal LG domain of the murine laminin α1 chain to a region between the K-L and L-M loops of the mouse laminin α1 chain, which we found to be in the connecting loop between the K and L strands of the human laminin α2 chain. However, Ln2-LG3-P2-DN3 itself, a sequence of only nine amino acids, was interpreted to have no specific conformational structure from the computational structure prediction algorithm used in this study. Nonetheless, this non-structural sequence of nine amino acids was evaluated to be effective enough to provoke the intracellular events with approximately 104%, 57%, and 43% of the activity of its mother protein, laminin, in cell adhesion, spreading, and migration activities, respectively. Determined to be a bioactive core sequence for cellular responses in PC12 cells, Ln2-LG3-P2-DN3 was shown to have effective cellular responses in a broad range of cell types, including osteoblasts, which indicated the potential for the biomedical application of this peptide. The
Ln2-LG3-P2-DN3 sequence, PPFEGCIWN, was considered to use the phosphorylation of PKCδ for the intracellular events, similar to the Ln2-LG3-P2 sequence, RNIPPFEGCIWN [17] . Also, another functional peptide derived from the LG1 domain of the human laminin α2 chain, DLTIDDSYWYRI, was previously shown to trigger the intracellular events via PKCδ phosphorylation [16] . A new hypothesis, based on a recent summary for allostery, may unify those results ( Considering that the final goal of peptide development is biomedical application, and several challenges, such as the risk of immunogenicity of peptide-treated scaffolds, should first be overcome, the antigenicity of the peptides and their effects on the inflammatory phase of wound healing must be investigated. Thus, this study examined the antigenicity and/or inflammatory response to the scaffolds treated with the peptides in full-thickness skin wounds. In this study, Ln2-LG3-P2-DN3, a short synthetic nonapeptide that was identified as a biologically active core sequence, showed no significant differences in the number of infiltrating inflammatory cells as compared to the vehicle. In addition, there were no multinucleated foreign body giant cells found. These results are consistent with previous reports demonstrating that bioactive short peptides induce cellular responses without immunoreactivity [21, 30, 32, 35] . Although functions and potential applications of several proteins have been presented, the use of macromolecules for therapeutics is associated with many disadvantages, such as poor bioavailability, the neutralization of antibody production, low stability, and a risk of severe side effects from the antigen-antibody reaction. They also have cost and insurance issues stemming from their high expense [36] . Peptides can potentially offer effective treatments that are able to address these issues, because they are small molecules and can be produced by fully synthetic chemical methods instead of by biological purification [7] . Our findings indicated that Ln2-
LG3-P2-DN3 may have low or no antigenicity, which makes the PPFEGCIWN motif promising in the field of tissue engineering and regenerative medicine, because a protein, like a laminin itself, is usually an antigen. significantly promoted new bone formation by enhancing bone volume, area, and thickness. The applicability of this peptide was also estimated in this study by using it to coat Ti, which is the most widely used material in orthopedic implants and dental endoprostheses. The improved indices, implying advanced bone healing, were found in vitro on the Ln2-LG3-P2-DN3-treated Ti surface; we found enhanced bone cell attachment and spreading, heightened gene expression of osteogenic markers, and increased ALP activity of osteogenic cells. Also, the promising results were shown in the in vivo experiment, which used the rabbit tibia model and the Ln2-LG3-P2-DN3-treated Ti implants without blocking that is more appropriate than implants with blocking for use in clinical contexts [37] . Accelerated bone responses were confirmed around the peptide-treated implants both quantitatively (BIC ratio) and qualitatively (modified Goldner's Masson trichrome staining of collagen and ALP histochemistry of osteoblasts). These findings are consistent with those of previous studies reporting that the modification of biomaterials with bioactive peptides derived from extracellular matrix proteins led to new bone formation by increasing cell adhesion, osteoblast differentiation and biomineralization [38] , and that laminin-treated ceramic scaffolds activated osteogenesis by promoting the adhesion of osteoprogenitor cells [39, 40] . Considering those results regarding bone healing and the broad cell-type affinity of this peptide, the PPFEGCIWN motif has great potential for various tissue engineering and biomedical applications.
In summary, this study identified a bioactive core binding sequence, PPFEGCIWN, within the human laminin α2 chain. This motif showed an affinity for various cell types, including the cells that originated from the epithelium and from the connective tissue. Ln2-LG3-P2-DN3 promoted new bone formation in vivo with low or no antigenicity. The PPFEGCIWN-treated surface displayed a strong osteogenic effect in dental and orthopedic implant therapy regimens by stimulating osteoblast differentiation through increased ALP activity or expression, thus promoting osseointegration between the host bone and the implant surface. These results demonstrated the potential therapeutic value of the PPFEGCIWN motif for biomedical applications, especially for bone tissue engineering applications.
Conclusions
Our findings show that the PPFEGCIWN motif, which was identified as a biologically active core-binding sequence within the human laminin α2 chain, promoted cell adhesion and spreading of human osteogenic cells and osteoblast-like cells in the cytocompatibility assessment. Pure Ti surfaces treated with Ln2-LG3-P2-DN3 were functionally active in increasing ALP activity and osteogenic marker gene expression, as well as promoting cellular responses of human osteogenic cells. An assessment of bone formation revealed that the Ln2-LG3-P2-DN3 was effective in promoting bone formation by enhancing the bone area, bone volume, and thickness in critical-size rat calvarial defects.
The application of the Ln2-LG3-P2-DN3-treated Ti implants to rabbit tibia wounds significantly promoted osseointegration by enhancing the BIC ratio, indicating that Ln2-LG3-P2-DN3 could improve the biological performance of Ti implants and reduce the time required before the loading of loadbearing, bone contacting devices. LG3-P2-DN3-treated Ti implants in rabbit tibiae at one, two, and four weeks. Data are expressed as mean ± SD (n = 3). LG3-P2-treated Ti implant; Ln2-L`G3-P2-DN3, Ln2-LG3-P2-DN3-treated Ti implant. Bars = 100 μm. LG2
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